Emerging Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease: From Composition to Function

Clinical Gastroenterology and Hepatology

Volumn 17, Issue 2, 2019, Pages 296-306

  Sharpton, Suzanne R ^a   Ajmera, Veeral ^b   Loomba, Rohit ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Microbiota; Nonalcoholic Fatty Liver

Indexed keywords

ALCOHOL; AMINO ACID; BILE ACID; CHOLINE; SHORT CHAIN FATTY ACID; TOLL LIKE RECEPTOR;

ALCOHOL PRODUCTION; AMINO ACID METABOLISM; AMINO ACID SYNTHESIS; BILE ACID METABOLISM; ENDOTOXEMIA; GASTROINTESTINAL TRACT FUNCTION; HOST PATHOGEN INTERACTION; HUMAN; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; LIVER CELL CARCINOMA; LIVER FIBROSIS; MEDICAL RESEARCH; MICROBIAL COMMUNITY; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PERMEABILITY BARRIER; PHENOTYPE; REVIEW; SIGNAL TRANSDUCTION; VITAMIN METABOLISM;

EID: 85058965206     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2018.08.065     Document Type: Review

References (82)

1. Lynch, S.V., Pedersen, O., The human intestinal microbiome in health and disease. N Engl J Med 375 (2016), 2369–2379.
2. Schnabl, B., Brenner, D.A., Interactions between the intestinal microbiome and liver diseases. Gastroenterology 146 (2014), 1513–1524.
3. Yu, L.X., Schwabe, R.F., The gut microbiome and liver cancer: mechanisms and clinical translation. Nat Rev Gastroenterol Hepatol 14 (2017), 527–539.
4. García-Lezana, T., Raurell, I., Bravo, M., et al. Restoration of a healthy intestinal microbiota normalizes portal hypertension in a rat model of nonalcoholic steatohepatitis. Hepatology 67 (2018), 1485–1498.
5. Gilbert, J.A., Blaser, M.J., Caporaso, J.G., et al. Current understanding of the human microbiome. Nat Med 24 (2018), 392–400.
6. Knight, R., Vrbanac, A., Taylor, B.C., et al. Best practices for analysing microbiomes. Nat Rev Microbiol 16 (2018), 410–422.
7. Zhu, L., Baker, S.S., Gill, C., et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis patients: a connection between endogenous alcohol and NASH. Hepatology 57 (2013), 601–609.
8. Michail, S., Lin, M., Frey, M.R., et al. Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease. FEMS microbiology ecology 91 (2015), 1–9.
9. Del Chierico, F., Nobili, V., Vernocchi, P., et al. Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach. Hepatology 65 (2017), 451–464.
10. Nobili, V., Putignani, L., Mosca, A., et al. Bifidobacteria and lactobacilli in the gut microbiome of children with non-alcoholic fatty liver disease: which strains act as health players?. Arch Med Sci 14 (2018), 81–87.
11. Raman, M., Ahmed, I., Gillevet, P.M., et al. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 11 (2013), 868–875.
12. Wong, V.W.-S., Tse, C.-H., Lam, T.T.-Y., et al. Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis: a longitudinal study. PloS One, 8, 2013, e62885.
13. Mouzaki, M., Wang, A.Y., Bandsma, R., et al. Bile acids and dysbiosis in non-alcoholic fatty liver disease. PloS One, 11, 2016, e0151829.
14. Boursier, J., Mueller, O., Barret, M., et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology 63 (2016), 764–775.
15. Wang, B., Jiang, X., Cao, M., et al. Altered fecal microbiota correlates with liver biochemistry in nonobese patients with non-alcoholic fatty liver disease. Sci Rep, 6, 2016, 32002.
16. Shen, F., Zheng, R.D., Sun, X.Q., et al. Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease. Hepatobiliary Pancreat Dis Int 16 (2017), 375–381.
17. Loomba, R., Seguritan, V., Li, W., et al. Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metab 25 (2017), 1054–1062.
18. Da Silva, H.E., Teterina, A., Comelli, E.M., et al. Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance. Sci Rep, 8, 2018, 1466.
19. Duarte, S.M.B., Stefano, J.T., Miele, L., et al. Gut microbiome composition in lean patients with NASH is associated with liver damage independent of caloric intake: a prospective pilot study. Nutr Metab Cardiovasc Dis 28 (2018), 369–384.
20. Ponziani, F.R., Bhoori, S., Castelli, C., et al. Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in non-alcoholic fatty liver disease. Hepatology, 2018 [Epub ahead of print].
21. Hoyles, L., Fernandez-Real, J.M., Federici, M., et al. Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women. Nat Med 24 (2018), 1070–1080.
22. Caussy, C., Hsu, C., Lo, M.-T., et al. Novel link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD. Hepatology, 2018 [Epub ahead of print].
23. Jiang, W., Wu, N., Wang, X., et al. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. Sci Rep, 5, 2015, 8096.
24. Million, M., Maraninchi, M., Henry, M., et al. Obesity-associated gut microbiota is enriched in Lactobacillus reuteri and depleted in Bifidobacterium animalis and Methanobrevibacter smithii. Int J Obes 36 (2012), 817–825.
25. Ottosson, F., Brunkwall, L., Ericson, U., et al. Connection between BMI-related plasma metabolite profile and gut microbiota. J Clin Endocrinol Metab 103 (2018), 1491–1501.
26. Schneeberger, M., Everard, A., Gomez-Valades, A.G., et al. Akkermansia muciniphila inversely correlates with the onset of inflammation, altered adipose tissue metabolism and metabolic disorders during obesity in mice. Sci Rep, 5, 2015, 16643.
27. Plovier, H., Everard, A., Druart, C., et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat Med 23 (2017), 107–113.
28. Pedersen, H.K., Gudmundsdottir, V., Nielsen, H.B., et al. Human gut microbes impact host serum metabolome and insulin sensitivity. Nature 535 (2016), 376–381.
29. Grat, M., Wronka, K.M., Krasnodebski, M., et al. Profile of gut microbiota associated with the presence of hepatocellular cancer in patients with liver cirrhosis. Transplant Proc 48 (2016), 1687–1691.
30. Li, J., Jia, H., Cai, X., et al. An integrated catalog of reference genes in the human gut microbiome. Nat Biotechnol 32 (2014), 834–841.
31. Maier, L., Pruteanu, M., Kuhn, M., et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 555 (2018), 623–628.
32. Jackson, M.A., Goodrich, J.K., Maxan, M.-E., et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut 65 (2016), 749–756.
33. Forslund, K., Hildebrand, F., Nielsen, T., et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 528 (2015), 262–266.
34. Nash, A.K., Auchtung, T.A., Wong, M.C., et al. The gut mycobiome of the Human Microbiome Project healthy cohort. Microbiome, 5, 2017, 153.
35. Mar Rodríguez, M., Pérez, D., Javier Chaves, F., et al. Obesity changes the human gut mycobiome. Sci Rep, 5, 2015, 14600.
36. Finucane, M.M., Sharpton, T.J., Laurent, T.J., et al. A taxonomic signature of obesity in the microbiome? Getting to the guts of the matter. PloS One, 9, 2014, e84689.
37. Abu-Ali, G.S., Mehta, R.S., Lloyd-Price, J., et al. Metatranscriptome of human faecal microbial communities in a cohort of adult men. Nat Microbiol 3 (2018), 356–366.
38. Le Chatelier, E., Nielsen, T., Qin, J., et al. Richness of human gut microbiome correlates with metabolic markers. Nature 500 (2013), 541–546.
39. Del Chierico, F., Nobili, V., Vernocchi, P., et al. Gut microbiota profiling of pediatric NAFLD and obese patients unveiled by an integrated meta-omics based approach. Hepatology 65 (2017), 451–464.
40. Pendyala, S., Walker, J.M., Holt, P.R., A high-fat diet is associated with endotoxemia that originates from the gut. Gastroenterology 142 (2012), 1100–1101.
41. Miele, L., Valenza, V., La Torre, G., et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 49 (2009), 1877–1887.
42. Rahman, K., Desai, C., Iyer, S.S., et al. Loss of junctional adhesion molecule A promotes severe steatohepatitis in mice on a diet high in saturated fat, fructose, and cholesterol. Gastroenterology 151 (2016), 733–746.
43. Bergheim, I., Weber, S., Vos, M., et al. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. J Hepatol 48 (2008), 983–992.
44. Hartmann, P., Seebauer, C.T., Mazagova, M., et al. Deficiency of intestinal mucin-2 protects mice from diet-induced fatty liver disease and obesity. Am J Physiol Gastrointest Liver Physiol 310 (2016), G310–G322.
45. Luck, H., Tsai, S., Chung, J., et al. Regulation of obesity-related insulin resistance with gut anti-inflammatory agents. Cell Metab 21 (2015), 527–542.
46. Henao-Mejia, J., Elinav, E., Jin, C., et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482 (2012), 179–185.
47. Diehl, A.M., Harrison, S., Caldwell, S., et al. JKB-121 in patients with nonalcoholic steatohepatitis: a phase 2 double blind randomized placebo control study. J Hepatol, 68, 2018, S103.
48. Blumberg, H., McCollum, E.V., The prevention by choline of liver cirrhosis in rats on high fat, low protein diets. Science 93 (1941), 598–599.
49. Corbin, K.D., Zeisel, S.H., Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression. Curr Opin Gastroenterol 28 (2012), 159–165.
50. Stremmel, W., Schmidt, K.V., Schuhmann, V., et al. Blood trimethylamine-N-oxide originates from microbiota mediated breakdown of phosphatidylcholine and absorption from small intestine. PloS One, 12, 2017, e0170742.
51. Romano, K.A., Vivas, E.I., Amador-Noguez, D., et al. Intestinal microbiota composition modulates choline bioavailability from diet and accumulation of the proatherogenic metabolite trimethylamine-N-oxide. mBio, 6, 2015, e02481.
52. Rath, S., Heidrich, B., Pieper, D.H., et al. Uncovering the trimethylamine-producing bacteria of the human gut microbiota. Microbiome, 5, 2017, 54.
53. Dumas, M.-E., Barton, R.H., Toye, A., et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci U S A 103 (2006), 12511–12516.
54. Spencer, M.D., Hamp, T.J., Reid, R.W., et al. Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology 140 (2011), 976–986.
55. Tang, W.H.W., Wang, Z., Levison, B.S., et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med 368 (2013), 1575–1584.
56. Martinez, K.B., Leone, V., Chang, E.B., Microbial metabolites in health and disease: Navigating the unknown in search of function. J Biol Chem 292 (2017), 8553–8559.
57. Canfora, E.E., Jocken, J.W., Blaak, E.E., Short-chain fatty acids in control of body weight and insulin sensitivity. Nat Rev Endocrinol 11 (2015), 577–591.
58. Ríos-Covián, D., Ruas-Madiedo, P., Margolles, A., et al. Intestinal short chain fatty acids and their link with diet and human health. Front Microbiol, 7, 2016, 185.
59. Schwiertz, A., Taras, D., Schäfer, K., et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity 18 (2010), 190–195.
60. Patil, D.P., Dhotre, D.P., Chavan, S.G., et al. Molecular analysis of gut microbiota in obesity among Indian individuals. J Biosci 37 (2012), 647–657.
61. Salazar, N., Dewulf, E.M., Neyrinck, A.M., et al. Insulin-type fructans modulate intestinal Bifidobacterium species populations and decrease fecal short-chain fatty acids in obese women. Clin Nutr 34 (2015), 501–507.
62. Chambers, E.S., Viardot, A., Psichas, A., et al. Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults. Gut 64 (2015), 1744–1754.
63. Vrieze, A., Van Nood, E., Holleman, F., et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 143 (2012), 913–916.
64. Mattace Raso, G., Simeoli, R., Russo, R., et al. Effects of sodium butyrate and its synthetic amide derivative on liver inflammation and glucose tolerance in an animal model of steatosis induced by high fat diet. PloS One, 8, 2013, e68626.
65. Slijepcevic, D., van de Graaf, S.F.J., Bile acid uptake transporters as targets for therapy. Dig Dis 35 (2017), 251–258.
66. Ridlon, J.M., Harris, S.C., Bhowmik, S., et al. Consequences of bile salt biotransformations by intestinal bacteria. Gut Microbes 7 (2016), 22–39.
67. Urdaneta, V., Casadesus, J., Interactions between bacteria and bile salts in the gastrointestinal and hepatobiliary tracts. Front Med, 4, 2017, 163.
68. Jiang, C., Xie, C., Li, F., et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J Clin Invest 125 (2015), 386–402.
69. Jia, W., Xie, G., Jia, W., Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nat Rev Gastroenterol Hepatol 15 (2018), 111–128.
70. Wahlström, A., Kovatcheva-Datchary, P., Ståhlman, M., et al. Crosstalk between bile acids and gut microbiota and its impact on farnesoid X receptor signalling. Dig Dis 35 (2017), 246–250.
71. Neuschwander-Tetri, B.A., Loomba, R., Sanyal, A.J., et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385 (2015), 956–965.
72. Ferslew, B.C., Xie, G., Johnston, C.K., et al. Altered bile acid metabolome in patients with nonalcoholic steatohepatitis. Dig Dis Sci 60 (2015), 3318–3328.
73. Jiao, N., Baker, S.S., Chapa-Rodriguez, A., et al. Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD. Gut 67 (2017), 1881–1891.
74. Baker, S.S., Baker, R.D., Liu, W., et al. Role of alcohol metabolism in non-alcoholic steatohepatitis. PloS One, 5, 2010, e9570.
75. Elshaghabee, F.M.F., Bockelmann, W., Meske, D., et al. Ethanol production by selected intestinal microorganisms and lactic acid bacteria growing under different nutritional conditions. Front Microbiol, 7, 2016, 47.
76. Engstler, A.J., Aumiller, T., Degen, C., et al. Insulin resistance alters hepatic ethanol metabolism: studies in mice and children with non-alcoholic fatty liver disease. Gut 65 (2016), 1564–1571.
77. Wang, T.J., Larson, M.G., Vasan, R.S., et al. Metabolite profiles and the risk of developing diabetes. Nat Med 17 (2011), 448–453.
78. Menni, C., Fauman, E., Erte, I., et al. Biomarkers for type 2 diabetes and impaired fasting glucose using a nontargeted metabolomics approach. Diabetes 62 (2013), 4270–4276.
79. Lavekar, A., Raje, D., Manohar, T., et al. Role of probiotics in the treatment of nonalcoholic fatty liver disease: a meta-analysis. Eur J Hepatogastroenterol 7 (2017), 130–137.
80. Clinicaltrials.gov, Identifier: NCT02721264.
81. Clinicaltrials.gov, Identifier: NCT02469272.
82. Kootte, R.S., Levin, E., Salojärvi, J., et al. Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition. Cell Metab 26 (2017), 611–619.